Jefferies Reiterates Buy on Allscripts (MDRX) Following Investor Day

Jefferies reiterated a Buy rating and $16.50 price target on Allscripts (NASDAQ: MDRX) following the company's investor day.

Analyst Sean Dodge commented, "MDRX is firmly on a path toward more sustainable revenue growth which when coupled with its lean cost structure should enable LT EPS growth in the 12-15% (annually) range. The macro outlook is clouded by greater uncertainty for providers and the NT expectations for VBC, but MDRX has enough growth levers at its disposable to at least make the low-end of its targeted ranges achievable."

For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.

Shares of Allscripts closed at $12.30 yesterday.

You May Also Be Interested In

• BofA Securities Starts Dollarama Inc. (DOL:CN) (DLMAF) at Buy
• National Health Investors (NHI) PT Lowered to $81 at Truist Securities
• The Lovesac Co. (LOVE) PT Raised to $20 at DA Davidson Following Q1 Results